1-溴-4,5-二氯-2-硝基苯 | 93361-94-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-4,5-二氯-2-硝基苯
• 中文别名: 2-溴-4,5-二氯硝基苯
• 英文名称: 1-bromo-4,5-dichloro-2-nitrobenzene
• 英文别名: 2-bromo-4,5-dichloronitrobenzene；1-bromo-4,5-dichloro-2-nitro-benzene；1-Brom-4,5-dichlor-2-nitro-benzol
• CAS: 93361-94-5
• 化学式: C₆H₂BrCl₂NO₂
• 分子量: 270.897
• InChiKey: NDJFXRVGCQJCSF-UHFFFAOYSA-N

物化性质

• 熔点：
  58-62 °C(Solv: chloroform (67-66-3); ethanol (64-17-5))
• 沸点：
  274.2±35.0 °C(Predicted)
• 密度：
  1.916±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-4,5-dichloro-2-nitrobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-4,5-dichloro-2-nitrobenzene
CAS number: 93361-94-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H2BrCl2NO2
Molecular weight: 270.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-溴-4,5-二氯-2-硝基苯 在 红铝 吡啶 、 potassium cyanide 、 copper(l) iodide 、 氯化亚砜 、 硫酸 、 铁粉 、 铜 、 sodium carbonate 、 potassium carbonate 、 氯化铵 、 copper(l) chloride 、 sodium nitrite 作用下， 以 乙醇 、 氯仿 、 水 、 溶剂黄146 、 苯 为溶剂， 反应 113.5h， 生成 (4,5-Dichloro-2-phenylsulfanyl-phenyl)-acetonitrile
  参考文献：
  名称：

  Potential noncataleptic neuroleptic agents: 2,3-Dichloro-10-[4-(2-hydroxyethyl)piperazino]-10,11-dihydrobenzo[b,f]thiepin

  摘要：

  通过对3,4-二氯溴苯进行硝化反应得到的6-硝基衍生物V，经胺VI和腈VII转化为2-溴-4,5-二氯苯甲酸(IX)。在3-甲基-1-丁醇中，在碳酸钾和铜及碘化亚铜的催化下，与硫代苯酚发生反应，得到4,5-二氯-2-(苯硫基)苯甲酸(Xa)，进而还原为醇XIa。经过未表征的中间体XIIa和XIIIa，转化为同系物酸XIVa。在150°C下，经过多磷酸环化，得到2,3-二氯二苯并[bf]噻吩-10(11H)-酮(XV)，再还原为醇XVI。经氢氯酸处理得到不稳定的氯衍生物XVII，其与1-(2-羟乙基)哌嗪发生取代反应，形成标题化合物II。其二甲磺酸盐呈现出略有毒性和非痉挛镇静药的特性。由于在大剂量下不影响大鼠脑中多巴胺代谢，因此不能被视为一种神经阻滞剂。

  DOI：

  10.1135/cccc19840992
• 作为产物：
  描述：

  3,4-二氯溴苯 在 硝酸 作用下， 反应 3.0h， 生成 1-溴-4,5-二氯-2-硝基苯
  参考文献：
  名称：

  Potential noncataleptic neuroleptic agents: 2,3-Dichloro-10-[4-(2-hydroxyethyl)piperazino]-10,11-dihydrobenzo[b,f]thiepin

  摘要：

  通过对3,4-二氯溴苯进行硝化反应得到的6-硝基衍生物V，经胺VI和腈VII转化为2-溴-4,5-二氯苯甲酸(IX)。在3-甲基-1-丁醇中，在碳酸钾和铜及碘化亚铜的催化下，与硫代苯酚发生反应，得到4,5-二氯-2-(苯硫基)苯甲酸(Xa)，进而还原为醇XIa。经过未表征的中间体XIIa和XIIIa，转化为同系物酸XIVa。在150°C下，经过多磷酸环化，得到2,3-二氯二苯并[bf]噻吩-10(11H)-酮(XV)，再还原为醇XVI。经氢氯酸处理得到不稳定的氯衍生物XVII，其与1-(2-羟乙基)哌嗪发生取代反应，形成标题化合物II。其二甲磺酸盐呈现出略有毒性和非痉挛镇静药的特性。由于在大剂量下不影响大鼠脑中多巴胺代谢，因此不能被视为一种神经阻滞剂。

  DOI：

  10.1135/cccc19840992

文献信息

• [EN] SHMT INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE SHMT ET LEURS UTILISATIONS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2018106636A1

  公开（公告）日：2018-06-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• Identification and Optimization of Anthranilic Sulfonamides as Novel, Selective Cholecystokinin-2 Receptor Antagonists
  作者：Brett D. Allison、Victor K. Phuong、Laura C. McAtee、Mark Rosen、Magda Morton、Clodagh Prendergast、Terry Barrett、Guy Lagaud、Jamie Freedman、Lina Li、Xiaodong Wu、Hariharan Venkatesan、Marna Pippel、Craig Woods、Michèle C. Rizzolio、Michael Hack、Kenway Hoey、Xiaohu Deng、Christopher King、Nigel P. Shankley、Michael H. Rabinowitz

  DOI：10.1021/jm060590x

  日期：2006.10.1

  A high throughput screening approach to the identification of selective cholecystokinin-2 receptor (CCK-2R) ligands resulted in the discovery of a novel series of antagonists, represented by 1-[2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-5-chlorobenzoyl]-piperidine (1; CCK-2R, pK(I) = 6.4). Preliminary exploration of the structure-activity relationships around the anthranilic ring and the amide and

  一种高通量筛选方法，用于鉴定选择性胆囊收缩素2受体（CCK-2R）配体，从而发现了一系列新型的拮抗剂，以1- [2-[（2,1,3-benzothiadiazol-4- （磺酰基）氨基] -5-氯苯甲酰基]-哌啶（1； CCK-2R，pK（I）＝ 6.4）。对邻氨基苯甲酸环以及酰胺和磺酰胺基团周围的结构活性关系的初步探索导致受体亲和力提高了近50倍，并且相对于相关的胆囊收缩素1受体显示出超过1000倍的选择性。药代动力学评估导致鉴定了4- [4-碘-2-[（5-喹喔啉基磺酰基）氨基]苯甲酰基]-吗啉，26d，
• Benzo[1,2,5]thiadiazole compounds
  申请人：——

  公开号：US20040224983A1

  公开（公告）日：2004-11-11

  Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

  某些氨基苯基硫基氨基苯并［1,2,5］噻二唑化合物是CCK2调节剂，可用于治疗CCK2介导的疾病。
• X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors
  作者：Michael R. Witten、Lisa Wissler、Melanie Snow、Stefan Geschwindner、Jon A. Read、Nicholas J. Brandon、Angus C. Nairn、Paul J. Lombroso、Helena Käck、Jonathan A. Ellman

  DOI：10.1021/acs.jmedchem.7b01292

  日期：2017.11.22

  point to the promising potential of STEP as a target for drug discovery in Alzheimer’s treatment. We previously reported a substrate-based approach to the development of low molecular weight STEP inhibitors with Ki values as low as 7.8 μM. Herein, we disclose the first X-ray crystal structures of inhibitors bound to STEP and the surprising finding that they occupy noncoincident binding sites. Moreover

  在包括阿尔茨海默氏病在内的许多神经精神疾病中已检测到大脑中纹状体富集的蛋白酪氨酸磷酸酶（STEP）的过度活性。值得注意的是，在阿尔茨海默病小鼠模型中，STEP的敲低导致下游STEP底物的磷酸化水平增加，并且观察到的认知和记忆缺陷明显逆转。这些数据表明，STEP作为阿尔茨海默氏病治疗药物发现目标的潜力巨大。我们之前曾报道过使用基于底物的方法开发具有K i的低分子量STEP抑制剂值低至7.8μM。在此，我们公开了与STEP结合的抑制剂的第一个X射线晶体结构，以及令人惊讶的发现，即它们占据了非一致的结合位点。此外，我们利用这种结构信息来优化抑制剂结构，以使K i达到110 nM，在一系列磷酸酶上具有15-60倍的选择性。
• BENZO[1,2,5]THIADIAZOLE COMPOUNDS
  申请人：Allison Brett

  公开号：US20070276016A1

  公开（公告）日：2007-11-29

  Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

  某些 amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole 化合物是CCK2调节剂，可用于治疗CCK2介导的疾病。